DRI Healthcare Trust (TSE:DHT.UN) Given New C$22.00 Price Target at Raymond James

DRI Healthcare Trust (TSE:DHT.UN) had its price objective reduced by investment analysts at Raymond James from C$23.00 to C$22.00 in a report issued on Wednesday,BayStreet.CA reports. Raymond James’ target price suggests a potential upside of 67.56% from the company’s previous close.

Several other research analysts have also issued reports on DHT.UN. Scotiabank lifted their price target on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Truist Financial lowered their price objective on shares of DRI Healthcare Trust from C$17.00 to C$14.00 in a research report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of C$18.00.

DRI Healthcare Trust Stock Down 1.2 %

Shares of DRI Healthcare Trust stock traded down C$0.16 on Wednesday, reaching C$13.13. 22,389 shares of the company were exchanged, compared to its average volume of 43,382. The company’s 50-day moving average is C$13.24 and its two-hundred day moving average is C$13.64. DRI Healthcare Trust has a 1-year low of C$10.39 and a 1-year high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.